Michiel C.T. van Zeijl

Author

The Netherlands Cancer Institute ORCID

Also Known As

M.C.T. van Zeijl, Michiel C. T. van Zeijl, Michiel C.T. van Zeijl

Publications

829

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Medisch Centrum Leeuwarden Radboud University Nijmegen Dutch Institute for Clinical Auditing University Medical Center Utrecht

About

Michiel C.T. van Zeijl is an author at The Netherlands Cancer Institute specializing in medicine, oncology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	118
2	Pathology	4	4	90
3	Cancer Therapeutics	3	3	69
4	Surgical Oncology	2	2	49
5	Cancer Epidemiology	2	2	54

Michiel C.T. van Zeijl

Publications

412

Citations

H-Index

Page 1

	Year	Citations
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Annals of Internal Medicine	2021	103
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH? Maartje G. Schouwenburg, Karijn P.M. Suijkerbuijk, Rutger H.T. Koornstra, Cancers	2019	41
Real‐world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials Michiel C.T. van Zeijl, Rawa K. Ismail, Liesbeth C. de Wreede, International Journal of Cancer	2020	36
Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry Anouk Jochems, Monique K. van der Kooij, Marta Fiocco, Cancers	2019	31
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes Maartje G. Schouwenburg, Anouk Jochems, B Leeneman, Melanoma Research	2018	30
Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry Michiel C.T. van Zeijl, Liesbeth C. de Wreede, Alfons J.M. van den Eertwegh, European Journal of Cancer Surgical OncologySurvival OutcomesCancer EpidemiologyMedicineCancer Management	2020	28
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study Michiel C.T. van Zeijl, John B.A.G. Haanen, Michel W.J.M. Wouters, Journal of Immunotherapy Normal Lactate DehydrogenaseCancer ManagementPathologyCancer RegistrationDermatology	2020	26
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors Rawa K. Ismail, Karijn P.M. Suijkerbuijk, Anthonius de Boer, Melanoma Research Neuro-oncologyReal-world PatientsMedicineBraf-mek InhibitorsMelanoma	2022	26
Discontinuation of <scp>anti‐PD</scp>‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice Michiel C.T. van Zeijl, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, International Journal of Cancer	2021	24
Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study Michiel C.T. van Zeijl, Florine L. Boer, Mariëtte I.E. van Poelgeest, European Journal of Cancer Surgical OncologySurvival OutcomesNationwide Population-based StudyMedicineCancer Management	2020	21

Page 1